Literature DB >> 9764042

The life and death of Helicobacter pylori.

D Scott1, D Weeks, K Melchers, G Sachs.   

Abstract

The ability of Helicobacter pylori to survive in the varying acidity of the stomach is considered to be linked to its ability to maintain a tolerable pH in its periplasmic space by acid dependent activation of internal urease activity. Whereas survival of H pylori can occur between a periplasmic pH of 4.0 to 8.0, growth can only occur between a periplasmic pH of 6.0 to 8.0. When urease activity is only able to elevate periplasmic pH to between 4.0 and 6.0, the organisms will survive but not divide. In the absence of division, antibiotics such as clarithromycin and amoxycillin are ineffective. Proton pump inhibitors, by elevating gastric pH, would increase the population of dividing organisms and hence synergise with these antibiotics.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9764042      PMCID: PMC1766596          DOI: 10.1136/gut.43.2008.s56

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  15 in total

Review 1.  Eradication of Helicobacter pylori.

Authors:  A T Axon
Journal:  Scand J Gastroenterol Suppl       Date:  1996

2.  Surface localization of Helicobacter pylori urease and a heat shock protein homolog requires bacterial autolysis.

Authors:  S H Phadnis; M H Parlow; M Levy; D Ilver; C M Caulkins; J B Connors; B E Dunn
Journal:  Infect Immun       Date:  1996-03       Impact factor: 3.441

3.  Prolonged ambulatory pH monitoring in patients with persistent gastroesophageal reflux disease symptoms: testing while on therapy identifies the need for more aggressive anti-reflux therapy.

Authors:  D A Katzka; V Paoletti; L Leite; D O Castell
Journal:  Am J Gastroenterol       Date:  1996-10       Impact factor: 10.864

4.  Changes in the intragastric distribution of Helicobacter pylori during treatment with omeprazole.

Authors:  R P Logan; M M Walker; J J Misiewicz; P A Gummett; Q N Karim; J H Baron
Journal:  Gut       Date:  1995-01       Impact factor: 23.059

5.  The effect of environmental pH on the proton motive force of Helicobacter pylori.

Authors:  K Meyer-Rosberg; D R Scott; D Rex; K Melchers; G Sachs
Journal:  Gastroenterology       Date:  1996-10       Impact factor: 22.682

6.  Hydrogen ion concentration in the mucus layer on top of acid-stimulated and -inhibited rat gastric mucosa.

Authors:  C Schade; G Flemström; L Holm
Journal:  Gastroenterology       Date:  1994-07       Impact factor: 22.682

7.  Pernicious anaemia and Campylobacter like organisms; is the gastric antrum resistant to colonisation?

Authors:  J F Flejou; P Bahame; A C Smith; R W Stockbrugger; J Rode; A B Price
Journal:  Gut       Date:  1989-01       Impact factor: 23.059

8.  Helicobacter pylori requires an acidic environment to survive in the presence of urea.

Authors:  M Clyne; A Labigne; B Drumm
Journal:  Infect Immun       Date:  1995-05       Impact factor: 3.441

9.  Effect of omeprazole--a gastric proton pump inhibitor--on pentagastrin stimulated acid secretion in man.

Authors:  T Lind; C Cederberg; G Ekenved; U Haglund; L Olbe
Journal:  Gut       Date:  1983-04       Impact factor: 23.059

Review 10.  Molecular biology of microbial ureases.

Authors:  H L Mobley; M D Island; R P Hausinger
Journal:  Microbiol Rev       Date:  1995-09
View more
  54 in total

1.  One-day front-loading with four doses of rabeprazole followed by a standard twice-daily regimen provides sufficient acid inhibition in extensive metabolizers of CYP2C19.

Authors:  Takuma Kagami; Mitsushige Sugimoto; Hitomi Ichikawa; Shu Sahara; Takahiro Uotani; Mihoko Yamade; Yasushi Hamaya; Moriya Iwaizumi; Satoshi Osawa; Ken Sugimoto; Hiroaki Miyajima; Takahisa Furuta
Journal:  Eur J Clin Pharmacol       Date:  2015-10-02       Impact factor: 2.953

2.  The oligo-acyl lysyl antimicrobial peptide C₁₂K-2β₁₂ exhibits a dual mechanism of action and demonstrates strong in vivo efficacy against Helicobacter pylori.

Authors:  Morris O Makobongo; Hanan Gancz; Beth M Carpenter; Dennis P McDaniel; D Scott Merrell
Journal:  Antimicrob Agents Chemother       Date:  2011-11-07       Impact factor: 5.191

Review 3.  Role of Helicobacter pylori in gastric cancer: Updates.

Authors:  Jahanarah Khatoon; Ravi Prakash Rai; Kashi Nath Prasad
Journal:  World J Gastrointest Oncol       Date:  2016-02-15

Review 4.  Second and third line treatment options for Helicobacter pylori eradication.

Authors:  Mingjun Song; Tiing Leong Ang
Journal:  World J Gastroenterol       Date:  2014-02-14       Impact factor: 5.742

5.  Effect of CYP2C19*17 gene variant on Helicobacter pylori eradication in peptic ulcer patients.

Authors:  Mateusz Kurzawski; Barbara Gawrońska-Szklarz; Joanna Wrześniewska; Andrzej Siuda; Teresa Starzyńska; Marek Droździk
Journal:  Eur J Clin Pharmacol       Date:  2006-08-16       Impact factor: 2.953

6.  Cure rate of Helicobacter pylori infection in Egyptian children related to CYP2C19 gene polymorphism.

Authors:  Ahmad Settin; Ahmad Fathy Abdalla; Ayman S Al-Hussaini; Rizk El-Baz; Amr Galal
Journal:  Indian J Gastroenterol       Date:  2014-03-08

Review 7.  Proton Pump Inhibitors in Gastroesophageal Reflux Disease: Friend or Foe.

Authors:  C Prakash Gyawali
Journal:  Curr Gastroenterol Rep       Date:  2017-09

8.  CYP2C19 genotype related effect of omeprazole on intragastric pH and antimicrobial stability.

Authors:  T Kita; Y Tanigawara; N Aoyama; T Hohda; Y Saijoh; F Komada; T Sakaeda; K Okumura; T Sakai; M Kasuga
Journal:  Pharm Res       Date:  2001-05       Impact factor: 4.200

9.  Furazolidone, co-amoxiclav, colloidal bismuth subcitrate, and esomeprazole for patients who failed to eradicate Helicobacter pylori with triple therapy.

Authors:  Zaigham Abbas; Javed Yakoob; Shahab Abid; Wasim Jafri; Muhammad Islam; Zahid Azam; Imran Hilal
Journal:  Dig Dis Sci       Date:  2008-12-05       Impact factor: 3.199

10.  Helicobacter pylori Eradication with Proton Pump Inhibitors or Potassium-Competitive Acid Blockers: The Effect of Clarithromycin Resistance.

Authors:  Hiroshi Matsumoto; Akiko Shiotani; Ryo Katsumata; Minoru Fujita; Rui Nakato; Takahisa Murao; Manabu Ishii; Tomoari Kamada; Ken Haruma; David Y Graham
Journal:  Dig Dis Sci       Date:  2016-09-22       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.